Table 6.
Model | CHD | Nephropathy | Retinopathy | Neuropathy | Stroke | Others |
---|---|---|---|---|---|---|
Name | ||||||
NIDDM [20] | The Framingham (CVD) [33] | WESDR [34], the Rochester Epidemiology Project [35] | WESDR [36, 37] | NHANES II [38], the Rochester Study (LEA) [39] | NR | NR |
DCEM [12] | Weinstein MC et al. [40], Anderson KM et al. [41], Hunink MGM et al. [42] | NR | NR | NR | Mostly from UKPDS [21], Eastman et al. [40, 43] | |
Archimedes [19] | ‘Features’ derived | |||||
CDM [27] | CVD: the Framingham [44] UKPDS [21], Herlitz et al. [45], the DIGAMI study [46]) Angina: the Framingham [166] CHF: the Framingham [44] PVD: the Framingham [44], PVD: the Framingham [44], | Wolfe RA et al. [47] | WESDR [36, 48], EURODIAB study [49] Cataract: UKPDS [50] | Partenen et al. [51, 52] | Petty et al. [53] Sprafka et al. [54] | Foot ulcer: Tennvall and Apelqvist [55] Hypoglycaemia: Poland and Israel 56, 57 |
UKPDS- OM1 [21] | All from UKPDS [21] | |||||
Michigan [9] | CHD:UKPDS [58], et al. [59], Ulvenstam G et al. [60], Lowel H et al. [61]Stevens RJ et al. [62] | Malmberg K Gall MA et al. [63] Ballard DJ et al. [35], Ravid M M et al. [64] | Klein R et al. [37, 65, 66], Moss SE et al. [67, 68] | Sands ML et al. [69], Adler AI et al. [70] | UKPDS [58], Hier DB et al. [71], Sacco RL et al. [72], Kothari V et al. [73] | Mortality: UKPDS [58] |
Cardiff [10] | Cardiff data [74] | Mostly from UKPDS [75] | ||||
ODEM [11] | All from GHC | |||||
Sheffield [22] | UKPDS [62] | DCCT [76] | NR | NR | UKPDS [73] | NR |
UKPDS- OM2 [28] | All from UKPDS [21, 28] | |||||
ECHO [24] | UKPDS [21] | Eastman et al. [43] | Eastman et al. [43] | Eastman et al. [43], Bagust et al. [77] | UKPDS [21] | NR |
IHE [23] | Macrovascular: NDR [78], UKPDS [21, 28] | Bagust A et al. [77] | Bagust A et al. [79] | Eastman R.C.et al. [20] | NR | Mortality: UKPDS [21, 28] |
COMT [26] | Gerstein HC et al.80 Wing RR et al. [81] | NR | NR | NR | NR | Perreault L et al. [82] |
CDS [25] | Mostly from ADVANCE [83] LDS [84], THIN85 |
NR not reported